This message was sent to ##Email##
|
|
|
|
|
| |
WMAR-TV
During a speech at South by Southwest, former Vice President Joe Biden urgently stressed the need for collaboration in cancer research.
"Guess what — the only bipartisan thing left in America is the fight against cancer," Biden said.
Biden's son, Beau, died of brain cancer in 2015.
Soon after, then-President Obama tasked Biden with putting together the Cancer Moonshot Task Force.
READ MORE
Cure
A small subset of patients may be prone to misclassification and receive the wrong treatment after new guidelines were set for the way that patients with breast cancer should be classified, said Michael F. Press, M.D., Ph.D., a member of the College of American Pathologists (CAP).
He has recommended changes to updated ASCO-CAP guidelines on assessment of HER2 amplification by fluorescence in situ hybridization (FISH).
READ MORE
|
Promoted by
|
|
|
|
 |
Medical News Today
Cancer is currently one of the top killers worldwide, and the number of cancer cases is only expected to rise. Although there are a number of therapies available, most of them are toxic and cause serious side effects. New research examines the impact of the natural vitamin C on cancer cell growth.
READ MORE
Medscape
When it comes to immunotherapy for cancer, "everyone likes to talk about the 'super-responders'" said an expert at the 10th Future of Genomic Medicine Conference. But evidence is emerging that some patients become "hyperprogressors" and their cancer grows quickly soon after they start therapy.
"We've all heard that immunotherapy is great. And there is a subset of patients who do really well with long-term remission, even in the metastatic setting," said Razelle Kurzrock, MD, from the University of California, San Diego School of Medicine. "But it's not all good."
READ MORE
| |
PRODUCT SHOWCASE | Advertisement
|
 |
|
Enjoy our journals? There’s an app for those! Journals such as those from the American Cancer Society ™, Journal of Surgical Oncology, Cancer Science and more are now available for your iPad and iPhone. Sample issues and abstracts, as well as open articles, can be accessed for free. A subscription to the journal is required to read the full text. Click here to learn more!
|
|
ACS Cancer Programs
March 22 is the new deadline for submitting a proposal for the 2017 Cancer Programs Conference: Creating a Culture of Quality. This conference, developed by the AJCC, CoC, NAPBC, NCDC, and ACS CRP, will focus on issues impacting healthcare providers committed to providing patients with cancer and breast disease high-quality, comprehensive, multi-disciplinary, patient-centered care. Plan to attend the conference Sept. 8-9 at the Hyatt Regency O'Hare in Rosemont (Chicago). Click here if you would like to be notified when conference registration opens.
READ MORE
The Associated Press via CBS
U.S. regulators have approved a new drug as an initial treatment for postmenopausal women with a type of advanced breast cancer.
The drug, called Kisqali and developed by Swiss drugmaker Novartis AG, is a pill that works to slow the spread of cancer by blocking two proteins that can stimulate growth and division of cancer cells.
It's for women who have metastatic breast cancer known as HR+/HER2-. About 40 percent of U.S. women diagnosed with breast cancer have this type, according to the American Cancer Society.
READ MORE
|
Promoted by
|
|
|
|
 |
ScienceDaily
A Washington State University researcher has found a way that prostate cancer cells hijack the body's bone maintenance, facilitating the spread of bone cancers present in some 90 percent of prostate-cancer fatalities. Working with colleagues at the Cedars-Sinai Medical Center and elsewhere, Jason Wu found that the process appears to respond to the same drugs found in certain antidepressants. The findings appear in the journal Cancer Cell.
READ MORE
NAPBC
Register today for the National Accreditation Program for Breast Centers (NAPBC) Accreditation Workshop: Pursuing Excellence through NAPBC Accreditation in Chicago on May 5. Designed for centers seeking accreditation for the first time and centers seeking re-accreditation, this program provides an overview of the survey process and enables you to:
- Discuss the NAPBC components and standards
- Describe what is expected prior to, during, and post-survey
- Explain the importance of quality improvement and how NAPBC makes a difference in this area
- Identify what is needed to achieve NAPBC accreditation from an administrator's point of view
This program has been approved by the National Cancer Registrars Association for 6.25 continuing education units.
READ MORE
 |
|
Doctors Without Borders/Médecins Sans Frontières (MSF) is actively recruiting general and trauma surgeons with experience in emergency obstetrics for international missions in developing countries. Learn more.
|
|
The Institute of Cancer Research
Patients who are cured of Hodgkin lymphoma are at a high risk of developing a second type of cancer, particularly if they have a family history of the disease, a major new study reports.
People who survived Hodgkin lymphoma were 2.4 times more likely to develop a second cancer of any type compared with people the same age and sex in the general population — and this risk remained high 30 years after treatment.
But the risk was even greater in people who were treated for Hodgkin lymphoma and had a family history of those specific cancers.
READ MORE
AJCC
If you are attending the Society of Surgical Oncologists (SSO) Annual Cancer Symposium in Seattle from March 15-18, plan to stop by booth number 2011 and meet the AJCC staff. Get the information you need about the AJCC Staging Manual Eight Edition.
READ MORE
NPR
Chemotherapy remains one of the mainstays of cancer treatment, but these harsh drugs are slowly being edged aside in medical research, as new treatments, like immunotherapy, grab the spotlight.
Still, this is not the end of the road for chemotherapy. For one thing, doctors are coming to realize that some of these drugs are useful for more than just killing cancer cells.
READ MORE
Medscape
Acupuncture is effective for the treatment of pain that is related to tumors and to cancer surgery but not pain due to chemotherapy, radiation therapy or hormone therapy, according to the largest meta-analysis to date on the use of the Chinese modality in this setting.
Tumors, which may press on bones or organs, and surgical incisions, which disrupt tissue, generally cause "nociceptive" pain, which means it is visceral and somatic and thus is more amenable to acupuncture, say the authors, led by H.Y. Chiu, PhD, RN, from the Taipei Medical University in Taiwan.
READ MORE
|
Missed last week's issue? See which articles your colleagues read most.
|
Don't be left behind. Click here to see what else you missed.
|
|
|
|
The Brief
Connect with AJCC
Connect with CoC
Connect with NAPBC
Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Ashley Harrington, Senior Content Editor, 469-420-2642 | Contribute news
Disclaimer: The Brief is a digest of news selected for the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC), both quality programs of the American College of Surgeons, from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The CoC and NAPBC do not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of the American College of Surgeons, the CoC and the NAPBC.
American College of Surgeons
633 N Saint Clair Street | Chicago, IL, 60611-3211 | 800-621-4111 | Contact Us
Learn how to add us to your safe sender list so our emails get to your inbox. |
|
| |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
